Feature

From the Field

Facilitating Physician Adherence to Clinical Pathways Across a Multi-Site Oncology Practice Network

02/16/2016

Brian J Gebhardt, MD

Sushil Beriwal, MD

Dwight E Heron, MD, MBA, FACRO, FACR

Abstract: With so many new developments in the field on oncology, physicians have a difficult time staying abreast of new guidelines and recommendations for different disease states. Clinical pathways are an...

...

02/16/2016

Journal of Clinical Pathways

Perspectives

Formulary Decisions and the Evolution of Psoriasis Treatment

12/14/2015

William Malatestinic, PharmD, MBA

David Amato, MD

Steven R. Feldman, MD, PhD

Abstract: Psoriasis is a common and significant illness characterized by systemic inflammation. In its mildest form, psoriasis can often be managed with relatively low-cost topical therapies; but for...

...

12/14/2015

Journal of Clinical Pathways

Research Reports

A Clinical Pathway to Reduce Time to Antibiotic Administration in Pediatric Cancer Patients With Fever and Potential Neutropenia

12/14/2015

Adam Lamble, MD

Thuan Nguyen MD, PhD

Susan Lindemulder, MD, MCR

David M. Spiro, MD, MPH

Suman Malempati, MD

Dawn Nolt, MD, MPH

Linda C. Stork, MD

Abstract: The authors developed a novel clinical pathway in the pediatric emergency department (PED) of Doernbecher Children’s Hospital, Oregon Health & Science University, that endorses administering...

...

12/14/2015

Journal of Clinical Pathways

Perspectives

The Use of Risk-Sharing Agreements to Manage Costs, Mitigate Risk, and Improve Value for Pharmaceutical Products

10/28/2015

Alex Bastian, MBA

Deeksha Dua, MBBS, MPH

Sahand Mirzahossein, MBA

In this article, the authors review the types of RSAs that have been implemented to date, with a specific focus on two European countries (the United Kingdom and Italy) and on the United States.

In this article, the authors...

10/28/2015

Journal of Clinical Pathways

Research Reports

The Use of Incremental Cost-Effectiveness Ratio Thresholds in Health Technology Assessment Decisions

10/27/2015

Merena Nanavaty, MS, BPharm

Satyin Kaura MSC, MBA

Mkaya Mwamburi, MD, PhD, MA [Econ]

Anagha Gogate, BA

John Proach, MBA

Abner Nyandege, PhD

Zeba M. Khan, RPh, PhD

Abstract: The incremental cost-effectiveness ratio (ICER) is used to determine the cost-effectiveness of new health care interventions. A literature review was conducted to determine the ICER thresholds used by...

...

10/27/2015

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Feature

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products